C4 Therapeutics Announces World-Class Scientific Advisory Board With Expertise In Therapeutics And The Ubiquitin-Proteasome System

Published: Nov 17, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--C4 Therapeutics (C4T) today announced Ken Anderson, M.D., Nathanael Gray, Ph.D., Christopher Kirk, Ph.D. and Eric Fischer, Ph.D. as the members of its Scientific Advisory Board (SAB).

“We are thrilled to have Ken, Nathanael, Chris, and Eric play an important role as our advisors at C4T,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Their world-renowned expertise in clinical oncology, drug discovery and development, and the basic-science of the ubiquitin-proteasome system will be invaluable as we both advance drug candidates toward the clinic and develop new tools and technologies that keep C4T at the cutting edge.”

Back to news